750 participants
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-10
- Start Date:
- 2026-03-12
- Completion:
- 2031-10-14
Conditions
- Non-Small Cell Lung Cancer (NSCLC)
Interventions
- DRUG
No Results Yet